Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.
EP. 1: Heart Failure Clinical and Economic Burden
An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.
EP. 2: The Progressive Nature of Heart Failure
An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.
EP. 3: Link Between LVEF, NT-ProBNP and Cardiac Remodeling
A discussion on the link between LVEF, nT-proBNP, and cardiac remodeling in predicting disease progression.
EP. 4: Improved Understanding of Heart Failure
A key opinion leader discusses how the medical understanding of heart failure has improved over the years and how it has helped management of disease.
EP. 5: Treatment Goals for Patients With Heart Failure
Expert physicians consider the treatment goals for patients with heart failure.
EP. 6: The HFrEF Standard of Care
An expert in the management of heart failure discusses the standard of care for patients with reduced ejection fraction.
EP. 7: Heart Failure Management Unmet Needs
Key opinion leaders provide an overview of the treatment gaps in the management of heart failure.
EP. 8: Utilization Management Strategies for Appropriate Treatment
A discussion on utilization management strategies for optimizing the treatment for patients with heart failure.
EP. 9: Challenges in the Management of HFpEF
Key opinion leaders enumerate the challenges of treating patients with HFpEF.
EP. 10: Differences in Standard of Care: HFpEF vs HFrEF
Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF.
EP. 11: Ensuring Timely and Appropriate Access to Therapy
A key opinion leader considers how to ensure patients with HFpEF and HFrEF receive therapy in a timely and appropriate manner.
EP. 12: Differences in Economic Burden: HFpEF and HFrEF
A discussion on how the economic burden of management differs for patients with HFpEF and HFrEF.
EP. 13: PROVE-HF Trial Overview
An expert physician provides an overview of the PROVE-HF trial and considers the practical implications for heart failure with reduced ejection fraction.
EP. 14: PARAGON-HF Trial Overview
An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile.
EP. 15: Recent Findings from the PARALLAX Study
An expert in the management of heart failure considers the importance of recent findings from the PARALLAX study.
EP. 16: Promising Findings From the TOPCAT Study
A discussion on the promising findings from the TOPCAT study.
EP. 17: Differences in Leading Treatments for Heart Failure
A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.
EP. 18: When to Add an SGLT2 Inhibitor to Treatment Regimen
A key opinion leader considers the optimal timing of adding an SGLT2 inhibitor to the treatment for patients with heart failure.
EP. 19: Heart Failure Sites of Care
A discussion on the optimal sites of care for patients with heart failure and how differing locations may alter treatment access.
EP. 20: How Approved Agents Will Change the Standard of Care
Expert physicians consider how novel agents will affect the treatment paradigm for heart failure.
EP. 21: Heart Failure Management During COVID-19
The program is closed with a discussion on how the coronavirus pandemic has affected the standard protocol for treating patients with heart failure.
2 Clarke Drive Cranbury, NJ 08512